Press Releases & News

Diasome Pharmaceuticals Launches Groundbreaking OPTI-2 Phase 2b Trial in Type 1 Diabetes

February 29, 2024

Diasome Pharmaceuticals Launches Groundbreaking OPTI-2 Phase 2b Trial in Type 1 Diabetes

February 29, 2024

Diasome Pharmaceuticals Appoints Peter Tollman, Ph.D., as Chairman of the Board

February 20, 2024

Diasome Pharmaceuticals Appoints Peter Tollman, Ph.D., as Chairman of the Board

February 20, 2024

Diasome Pharmaceuticals Announces First Closing of Series C Financing Round

December 7, 2023

Diasome Pharmaceuticals Announces First Closing of Series C Financing Round

December 7, 2023

Former Novo Nordisk Executive, Dr. Todd Hobbs, joins Diasome Pharmaceuticals as Chief Medical Officer

October 24, 2023

Former Novo Nordisk Executive, Dr. Todd Hobbs, joins Diasome Pharmaceuticals as Chief Medical Officer

October 24, 2023

Diasome's CMO, Dr. Marc Penn, to Unveil Innovative Diabetes Research at ADA Scientific Sessions

June 21, 2023

Diasome's CMO, Dr. Marc Penn, to Unveil Innovative Diabetes Research at ADA Scientific Sessions

June 21, 2023

The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime

June 2, 2022

The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime

Diasome Pharmaceuticals announces the addition of globally recognized biopharma thought leader and CEO advisor Peter Tollman, PhD as a new Board Member

Diasome Pharmaceuticals announces the addition of globally recognized biopharma thought leader and CEO advisor Peter Tollman, PhD as a new Board Member

January 13, 2022

Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase

Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase

August 4, 2020

Diasome to Present at the LifeSci Partners Summer Symposium

Diasome to Present at the LifeSci Partners Summer Symposium

July 28, 2020

Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

June 15, 2020

Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions

Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions

June 4, 2020

Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

February 18, 2020

Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference

Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference

February 12, 2020

Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board

Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board

December 10, 2019

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes

September 30, 2019

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes

A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.

September 26, 2019

A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.

Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.

Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.

September 24, 2019

Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

June 25, 2019

Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin

June 17, 2019

Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin

Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes

Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes

June 10, 2019

Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions

May 29, 2019

Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions

Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness

April 29, 2019

Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness

Diasome's Liver Targeted Insulin

April 18, 2019

Diasome's Liver Targeted Insulin

First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Technology for People with Type 1 Diabetes

March 28, 2019

First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Technology for People with Type 1 Diabetes

March 28, 2019

Developing Smarter Insulin to Treat Diabetes

February 28, 2019

Developing Smarter Insulin to Treat Diabetes

Diasome Pharmaceuticals, Inc. provides 16-month period company update

Diasome Pharmaceuticals, Inc. provides 16-month period company update

February 14, 2019

Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi

July 5, 2017

Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi

Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund

July 5, 2017

Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund

2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed

September 17, 2016

2016 Diabetes Symposium in Boston, Robert Geho interviewed by Diabetes in Control publisher Steve Freed

After Decades of work, Diasome's insulin additive enters 200-patient trial

August 28, 2016

After Decades of work, Diasome's insulin additive enters 200-patient trial

August 28, 2016

Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin

July 29, 2016

Diasome announces dosing of first type 1 diabetes patient in randomized phase 2b clinical trial of injectable hepatocyte direct vesicle (HDV) technology with insulin

July 29, 2016

Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership

March 15, 2016

Diasome Pharmaceuticals, Inc. and Lyfebulb, LLC Announce Partnership

March 15, 2016

Clinical trial design collaboration with Joslin Diabetes Center

April 27, 2015

Clinical trial design collaboration with Joslin Diabetes Center

April 27, 2015

Injected HDV insulin patent allowance

March 31, 2015

Injected HDV insulin patent allowance

March 31, 2015

Oral insulin technology patent issues

February 25, 2015

Oral insulin technology patent issues

February 25, 2015

The importance of the liver in insulin replacement therapy in insulin-deficient diabetes

May 1, 2014

The importance of the liver in insulin replacement therapy in insulin-deficient diabetes

May 1, 2014

McDonald Partners Engagement

April 9, 2014

McDonald Partners Engagement

April 9, 2014

A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus

February 27, 2014

A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral anti-diabetic treatment in patients with type 2 diabetes mellitus

The preparation and evaluation of tritiated polyalanyl insulin derivates

July 1, 2013

The preparation and evaluation of tritiated polyalanyl insulin derivates

July 1, 2013

Weight loss patent allowance

March 6, 2013

Weight loss patent allowance

March 6, 2013

Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation

November 1, 2009

Hepatic-Directed Vesicle Insulin: a review of formulation development and preclinical evaluation

November 1, 2009

Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus

January 9, 2009

Clinical trial summary: Single-Blind, Placebo-Controlled, Dose-Ranging trial of Oral HDV-Insulin in Patients with type 2 Diabetes Mellitus

January 9, 2009

A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus

June 1, 2008

A Two-Week randomized active comparator study of two HDV-Insulin routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus

June 1, 2008

Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes

June 1, 2008

Hepatic-Directed Vesicles-Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes

June 1, 2008

The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients

March 30, 2001

The effects of HDV-Insulin on carbohydrate metabolism in Type 1 Diabetic patients

March 30, 2001